This research is Trending!
PVI-SHAM-AFAtrial FibrillationThe LancetOpen Access
Catheter Ablation Versus Sham Procedure for Quality of Life in Atrial Fibrillation
Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial
View Full PaperWhy the trial?
Quality-of-life gains after AF catheter ablation had never been separated from placebo effect: no prior trial compared pulmonary vein isolation with a sham procedure under double-blind conditions.
Does catheter ablation improve atrial fibrillation-related quality of life more than a sham procedure in patients with symptomatic paroxysmal or persistent atrial fibrillation?
Population
262 adults with symptomatic paroxysmal or persistent AF (median 67; 51% female)
Comparison
Catheter ablation (PVI) vs double-blind sham procedure
Design
Double-blind, sham-controlled, multicentre randomized trial (2:1) at nine sites
Follow-up
6 months (median 184 days); 12-month follow-up ongoing
Key result
Catheter ablation did not demonstrate superiority over a sham procedure for improving atrial fibrillation-related quality of life at 6 months (MD 2.6; 95% CI -2.7 to 8.0; p=0.36).
Authors
Discussion
Key questions
From the author
Rolf Wachter5d ago
Hi everybody, I am the PI of PVI-SHAM-AF. Looking forward to discussing PVI-SHAM-AF with this community.
PVI-SHAM-AF co-authorMember takes
Where experts stand
Experts read PVI-SHAM-AF as a sobering reminder that ablation's clear rhythm benefit does not automatically translate into quality-of-life gains over a sham procedure, prompting real questions about how much of the symptomatic improvement patients report is contextual.
Most experts accept that ablation genuinely reduces AF burden but are struck by the failure to separate from sham on quality of life, the trial's primary endpoint. Several point to the sham arm's active elements (sedation, cardioversion, intensive follow-up) and baseline patient selection as factors that may have narrowed the gap. The live question is whether these results should change how clinicians counsel patients or whether differences in trial design explain the contrast with other sham-controlled ablation studies.
Agreement
Multiple clinicians agree that a large part of the symptomatic benefit patients experience after ablation may be contextual or placebo-driven, given the sham arm's strong quality-of-life improvement.
2 clinicians say this directly
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Still unclear
Experts question whether the sham arm's use of cardioversion inflated its quality-of-life response, and whether requiring more symptomatic patients at baseline (as other trials did) would have produced a different result. It remains unclear how these findings will interact with guideline recommendations that rest on ablation's symptomatic benefit.
Key expert perspectives
The sham arm was not "nothing" and that matters for interpretation
Marrouche cautions that the sham arm included deep sedation, an invasive cath-lab procedure, intensive follow-up, and cardioversion when patients were in AF. He argues this makes the comparator itself an effective rhythm-control intervention, complicating any conclusion that ablation lacks symptomatic benefit.
Distilled from their postX post
Higher baseline AFEQT and AF-type mix may have blunted the quality-of-life signal
Kyriacou notes that PVI-SHAM-AF had no AFEQT threshold for enrollment (baseline ~60), leaving less room to detect improvement compared with PFA-SHAM which required AFEQT ≤50. He also highlights the roughly 50:50 paroxysmal/persistent AF mix, contrasting it with other sham trials that enrolled predominantly one type.
Cardioversion alone may explain much of the success in persistent AF ablation trials
Futyma argues that cardioversion may account for a large share of outcomes in recent persistent AF ablation studies, and the sham arm of PVI-SHAM-AF supports this interpretation.
Distilled from their postX post
Overview
Ablation confers no quality-of-life benefit over sham at 6 months; challenges reliance on open-label trials for symptomatic AF.
Key Points
- To determine whether catheter ablation improves disease-related quality of life compared with a sham procedure in patients with symptomatic paroxysmal or persistent atrial fibrillation.
- Conducted a double-blind, multicentre, randomized trial (PVI-SHAM-AF; NCT05119231) across nine sites in Germany and Poland enrolling 262 patients randomly assigned 2:1 to catheter ablation (n=173) or a sham procedure (n=89).
- Evaluated patients with a median follow-up of 184 days (IQR 181–191) using an intention-to-treat primary analysis with missing data handled by multiple imputation.
- Assessed the primary endpoint as the between-group difference in change from baseline to 6 months in the Atrial Fibrillation Effect on the Quality-of-life Questionnaire (AFEQT) summary score.
- At 6 months, mean AFEQT scores increased from 61.3 (SD 20.1) to 81.1 (16.6) with ablation and from 59.2 (19.0) to 74.9 (19.5) with sham (Hodges–Lehmann estimate of difference in change: 2.6, 95% CI −2.7 to 8.0; p=0.36).
- One non-procedure-related death occurred in each group, and procedure-related serious adverse events occurred in 6 ablation patients and 4 sham patients (including one ischemic stroke in the sham group).
Evidence details
What drove the result?
| Outcome | Ablation | Sham |
|---|---|---|
| AFEQT summary score, baseline → 6 months | 61.3 → 81.1 | 59.2 → 74.9 |
| Primary · Hodges–Lehmann difference in change 2.6 (95% CI −2.7 to 8.0; p=0.36) — not superior to sham | ||
| Freedom from AF at 6 months | 73% | 52% |
| From the trial record; not reported in the publication abstract | ||
Limitations & tradeoffs
Safety
Procedure-related serious adverse events occurred in 6 vs 4 patients (including 1 ischaemic stroke in the sham group), with 1 death per arm (neither procedure-related).
Representation
Only 262 of 1199 invited patients consented, which may limit generalizability.
Statistical certainty
The confidence interval (−2.7 to 8.0) still allows a clinically relevant quality-of-life benefit.
Design limitations
Primary follow-up was 6 months (12-month follow-up ongoing), and the sham group also improved substantially (59.2 to 74.9), consistent with a strong placebo response.
Structured PICO
Does catheter ablation improve atrial fibrillation-related quality of life more than a sham procedure in patients with symptomatic paroxysmal or persistent atrial fibrillation?
P
Population
262 patients aged 18 years or older with symptomatic paroxysmal or persistent atrial fibrillation, followed for a median of 184 days.
I
Intervention
Catheter ablation
C
Comparator
Sham procedure
O
Outcome
Between-group difference in change from baseline to 6 months in the Atrial Fibrillation Effect on the Quality-of-life Questionnaire (AFEQT) summary scorepatient reported
In a sham-controlled trial of patients with symptomatic atrial fibrillation, catheter ablation did not significantly improve quality of life at 6 months compared to a sham procedure.
Main Result
Mean Difference: 2.6 (95% CI -2.7–8)
p-value: p=0.36
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Wachter et al. (2026) conducted an RCT in Symptomatic paroxysmal or persistent atrial fibrillation (n=262). Catheter ablation vs. Sham procedure was evaluated on Between-group difference in change from baseline to 6 months in the Atrial Fibrillation Effect on the Quality-of-life Questionnaire (AFEQT) summary score (MD 2.6, 95% CI -2.7 to 8.0, p=0.36). Catheter ablation did not demonstrate superiority over a sham procedure for improving atrial fibrillation-related quality of life at 6 months (MD 2.6; 95% CI -2.7 to 8.0; p=0.36).